MariMed Inc. (MRMD.CN)
| Previous Close | 0.6000 |
| Open | 0.0000 |
| Bid | 0.3400 x N/A |
| Ask | 0.5000 x N/A |
| Day's Range | 0.6000 - 0.6000 |
| 52 Week Range | 0.2000 - 0.7800 |
| Volume | |
| Avg. Volume | 34,591 |
| Market Cap | 225.078M |
| Beta (5Y Monthly) | 2.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings Date | May 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireStatement From MariMed CEO And President Jon Levine Regarding The Drug Enforcement Administration’s Decision To Recategorize Cannabis To Schedule III
NORWOOD, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- The following is a statement from Jon Levine, CEO and President of leading multi-state cannabis operator, MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD). “The impending announcement of the DEA’s decision to recategorize cannabis from Schedule I to Schedule III under the Controlled Substances Act is historic. The positive impact this will have cannot be overstated. Our industry, the millions of consumers and patients we serve, and the individ
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Village Farms regained Nasdaq compliance; Weedmaps is facing a compliance issue. MariMed expanded Maryland presence with a $5.3 million acquisition. Tilray adjusted expectations for 2024 amid financial challenges, as they eye Canadian tax relief. Key Takeaways; Psychedelic Sector Optimi Health partnered with a New Zealand institute to supply psilocybin for indigenous […]
- GlobeNewswire
MariMed Closes Acquisition of Thrive Dispensary in Casey, The Company’s Fifth Illinois Dispensary
NORWOOD, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced the closing of its acquisition of Allgreens Dispensary, LLC on April 9, 2024. The approval of the license transfer by the Illinois Department of Financial & Professional Regulation, and subsequent closing of the acquisition, allows MariMed to fully consolidate the financial results of the Company’s Thr
